Therapeutic Vaccination in Treated HIV Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

May 17, 2021

Study Completion Date

May 17, 2021

Conditions
HIV-1-infection
Interventions
BIOLOGICAL

PENNVAX-GP

PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.

BIOLOGICAL

INO-6145

INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.

BIOLOGICAL

INO-9012

The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.

DEVICE

CELLECTRA® 2000

Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.

Trial Locations (2)

90025

University of California, Los Angeles, Los Angeles

94110

Zuckerberg San Francisco General Hospital (ZSFG), San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

University of California, Los Angeles

OTHER

collaborator

Inovio Pharmaceuticals

INDUSTRY

lead

Steven Deeks

OTHER

NCT03606213 - Therapeutic Vaccination in Treated HIV Disease | Biotech Hunter | Biotech Hunter